Quality Control and validation issues

iii) What is the product impact of a non-homogenous process? What type of product complaint would result from a non-homogenous process (explain and give at least one specific example of a product complaint) iv) Why do you think FDA did not accept the use of a surrogate process for the validation (as noted in the warning letter)? Explain